The 2010 World Health Organization (WHO) classification recommends that pancreatic neuroendocrine tumors (Pan-NETs) be graded on the basis of the mitotic rate and Ki67 index, with grade 2 (G2) PanNETs defined as having a mitotic rate of 2 to 20 mitotic figures/10 high-power fields or a Ki67 index of 3% to 20%. Grade 3 (G3) pancreatic neuroendocrine carcinoma (NEC) is defined as having >20 mitotic figures/10 high-power fields or a Ki67 index of >20%. However, some PanNETs show discordance between the mitotic rate and Ki67 index, usually having a Ki67 index in the G3 range but a mitotic rate suggesting G2, prompting us to examine the clinical significance of the Ki67 index in a large series of clinically well-characterized mitotic G2 PanNETs. Mitotic G2 well differentiated PanNETs, surgically resected at our institutions were reviewed. Of those, 19 cases had a Ki67 > 20% and were selected as the study group of grade-discordant (mitotic count G2/Ki67 index G3) PanNETs. For comparison, 53 grade-concordant (both mitotic count and Ki67 index G2) PanNETs matched for presenting stage with the discordant group as well as 43 morphologically poorly differentiated (either small cell or large cell type) pancreatic NECs were also included. The percentage of Ki67-positive neoplastic cells was quantified by manual counting of at least 500 cells on printed photographic images of "hot spots." The mean Ki67 index for grade-concordant and grade-discordant PanNETs and poorly differentiated NECs were 8.1% (range, 3% to 20%), 40% (range, 24% to 80%), and 70% (range, 40% to 98%), respectively. Overall, patients with grade-discordant PanNETs had significantly longer survival time compared with the patients with poorly differentiated NEC (median survival of 54.1 vs. 11 mo and 5 y survival of 29.1% vs. 16.1%; P = 0.002). In addition, the survival time of the patients with grade-discordant PanNETs was shorter than that of the patients with grade-concordant PanNETs (median survival of 67.8 mo and 5 y survival of 62.4%); however, the difference was not statistically significant (P = 0.2). Our data support the notion that the mitotic rate and Ki67 index-based grades of PanNETs can be discordant, and when the Ki67 index indicates G3, the clinical outcome is slightly worse. More importantly, we demonstrate that well differentiated PanNETs that are G3 by Ki67 are significantly less aggressive than bona fide poorly differentiated NECs, suggesting that the current WHO G3 category is heterogenous, contains 2 distinct neoplasms, and can be further separated into well differentiated PanNET with an elevated proliferation rate and poorly differentiated NEC.
BACKGROUND
A grading system for all gastroenteropancreatic neuroendocrine tumors (NETs) based on mitotic count and Ki67-labeling index was proposed in 2007 by the European Neuroendocrine Tumor Society. 1 This system has since been modified and is now incorporated into the 2010 World Health Organization (WHO) classification of tumors of the digestive system, which divides neuroendocrine neoplasms of the tubular gastrointestinal tract, along with their pan-creatic counterparts, into grade 1 (G1) and grade 2 (G2) NETs and grade 3 (G3) neuroendocrine carcinoma (NEC). 2 G1 NETs have <2 mitotic figures/10 high-power fields (HPF) and a Ki67-labeling index of <3%, whereas G2 NETs have 2 to 20 mitotic figures/10 HPF or a Ki67labeling index of 3% to 20%. G3 NECs are defined by >20 mitotic figures/10 HPF or a Ki67-labeling index of >20%. 2 The mitotic rate and Ki67 index of a pancreatic neuroendocrine tumor (PanNET) are not always concordant. The 2010 WHO classification recommends that when mitotic rate and Ki67-labeling index indicate different grades, then the higher of the 2 should be used to assign the grade. This recommendation is supported, at the lower end of the grading spectrum (G1/G2), by a recent study, which demonstrated that patients with grade-discordant (mitotic count G1/Ki67 index G2) PanNETs have larger tumors with more aggressive histologic features, more metastases, and shorter overall survival (12 vs. 16.7 y; P < 0.01), compared with patients with grade-concordant (both mitotic count and Ki67 index G1) PanNETs. 3 However, there is no study that has systematically assessed the clinical behavior of gradediscordant neuroendocrine tumors at the high-grade end of the spectrum (G2/G3).
In addition, tumor differentiation based on morphology is not explicitly considered in the 2010 WHO classification system. The terminology of "neuroendocrine carcinoma" for G3 neoplasms implies that they are histologically poorly differentiated, but some morphologically well differentiated NETs also have proliferative rates (usually the Ki67 index) that meet the threshold for G3 NECs. Moreover, a recent landmark study has shown that G3 NECs with a Ki67 index <55% do not respond to platinum-based chemotherapy, in contrast to G3 NECs with a Ki67 index >55%, 4 supporting the concept that the current WHO G3 category is heterogenous, and the tumors at the lower end of the G3 range are in fact well differentiated NETs with an elevated proliferative rate (or "high-grade, well differentiated NETs").
The purpose of this study was to asses clinicopathologic features and survival outcomes of morphologically well differentiated PanNETs ( Fig. 1 ) that are G2 by mitotic count but G3 by Ki67 index and to compare these grade-discordant tumors with gradeconcordant G2 PanNETs as well as to bona fide poorly differentiated (small cell or large cell type) pancreatic NECs (Fig. 2 ).
MATERIALS AND METHODS
The surgical pathology databases of our institutions (including University of Pittsburgh Medical Center where cases were collected by A.M.K.) were searched for cases with a diagnosis of well differentiated PanNETs/neoplasm/carcinoma from 1982 to 2013, and those with a mitotic rate Z2/10 HPF, with available clinical follow-up information, were identified. Within this group, 19 cases (all resections) had a Ki67 > 20% and were selected as the study group of grade-discordant (mitotic count G2/Ki67 index G3) well differentiated PanNETs. To determine whether this discordance in mitotic grade and Ki67 index was significant, clinicopathologic features, including survival, of these grade-discordant PanNETs were contrasted with those of 53 grade-concordant (both mitotic count and Ki67 index G2) well differentiated PanNETs (all resections) matched for the presenting stage with the grade-discordant group as well as 43 morphologically poorly differentiated (either small cell or large cell type, Figs. 2A, B ) NECs (all resections). Detailed clinicopathologic features of the latter have been reported previously. 5 Available medical records including pathology reports were reviewed to obtain clinical data including age, sex, associated genetic syndromes, clinical functionality, and distant metastases. All the hematoxylin and eosinstained slides were then reassessed using the diagnostic and grading criteria put forth by the 2010 WHO classification of neuroendocrine neoplasms of the digestive system. 2 The number of the tumor slides per case ranged between 5 and 18. The following histopathologic information was also reevaluated: tumor size; lymphovascular and perineural invasion; extension into the peripancreatic soft tissue, duodenal wall, or other adjacent organs; margin status; and number of total and metastasis-containing lymph nodes.
The mitotic rate of each case was determined by counting mitotic figures in 50 HPFs (at Â 400 on an Olympus microscope), expressed as the rate per 10 HPF.
A representative formalin-fixed paraffin-embedded tissue section of each tumor was immunolabeled using the standard avidin-biotin peroxidase method with an antibody against Ki67/MIB1 (DakoCytomation, Carpinteria, CA), using tonsillar tissue as the positive control. Each Ki67labeled tumor slide was scanned at Â 10 to identify the most intensely labeling regions (hot spots). The hot spot was photographed at Â 20, printed, and Ki67-positive and Ki67-negative tumor cells were then visualized, manually counted, and crossed off, using 2 different color markers as described previously. 6 At least 500 tumor cells were counted (O.B.), non-neoplastic nuclei not included, and a labeling index was calculated: %Ki67 = positive nuclei/total nuclei. All tumors were staged following the criteria defined by the seventh edition American Joint Cancer Committee cancer staging manual. 7 Overall survival data were obtained from hospital records or the United States Social Security Death Index. Causes of death for determining disease-specific survival were obtained from the National Death Index (National Center for Health Statistics, Hyattsville, MD), supplemented with medical chart review in cases for which a specific cause of death was not available in the National Death Index. Survival analyses were performed using the Kaplan-Meier method and log-rank (Mantel-Cox) comparison, with StatView software version 5.0 (SAS Institute, Cary, NC) and/or MedCalc version 13.1.2. (MedCalc Software bvba, Ostend, Belgium).
RESULTS

Clinical Features
The age and sex of the 21 patients with grade-discordant PanNETs (mean age = 54 y; male to female ratio = 1.7) were similar to those of the 53 patients with grade-concordant G2 PanNETs (mean age = 55 y; male to female ratio = 1.7) and those of the 43 patients with poorly differentiated NECs (mean age = 59; male to female ratio = 1.3) (P = 0.16 [1-way analysis of variance (ANOVA) for age] and P = 0.88 [w 2 test for sex], respectively). In terms of the associated genetic syndromes, only 4 patients with PanNETs (1 from grade-discordant group, 3 from grade-concordant group) had known MEN1 or von Hippel-Lindau syndromes ( Table 1) . None of the patients with poorly differentiated NEC had a known genetic syndrome except for 1 patient who carried a germline BRCA1 mutation.
Of those with available data, 1 grade-discordant (ectopic ACTH production) and 2 grade-concordant (1 gastrinoma, 1 insulinoma) PanNETs were functional. None of the poorly differentiated NECs were functional (Table 1 ).
Pathologic Features
The grade-discordant PanNETs, similar to the grade-concordant PanNETs, were located more common in the body or tail. In contrast, the majority of poorly differentiated NECs were located in the head of the pancreas (P = 0.04, w 2 test). The median tumor size of the grade-discordant PanNETs (4.5 cm) was similar to that of the grade-concordant PanNETs (4.3 cm) and of the poorly differentiated NECs (4.1 cm; P = 0.78, 1-way ANOVA).
Despite different growth patterns (diffuse, nested, trabecular, etc.), overall morphology, cytologic features, and distribution of mitotic figures were uniform throughout the tumors of grade-discordant group. Thus, no evidence of different grades within one tumor (ie, tumor progression) was identified.
Average mitotic rates (per 10 HPF) and average Ki67 indices of grade-discordant PanNETs (Fig. 3A) were higher than those of grade-concordant PanNETs (7.6/10 HPF vs. 3.5/10 HPF; and 40% vs. 8.1%), but only the latter reached statistical significance (P < 0.05, ANOVA post hoc Tukey-Kramer test). Of note, although the majority (71%) of grade-discordant PanNETs had Z30% Ki67 index, only 2 had >55% Ki67 index. However, the poorly differentiated NECs had a much higher average mitotic rate and a higher average Ki67 index ( Fig. 3B ) than the WHO-recommended minimum thresholds for the G3 category (51/10 HPF and 74% for small cell type and 37/10 HPF and 66% for large cell type) ( Table 2 ).
The majority of the neoplasms extended beyond the pancreas (pT3), usually into the peripancreatic soft tissue but also into the duodenum, portal vein, splenic vessels, There was no significant difference among the 3 groups in terms of prevalence of lymphovascular invasion and perineural invasion ( Table 1 , P = 0.28 and 0.35, respectively, w 2 test). However, of cases with known lymph node status, 8 of 17 (47%) grade-discordant PanNETs had lymph node metastases, compared with 27 of 52 (52%) grade-concordant PanNETs (P = 0.79, Fisher exact test), and 34 of 40 (85%) had poorly differentiated NECs (P = 0.004, Fisher exact test).
Distant metastasis rates were also similar among the 3 groups: Of cases in which information on distant metastases was available at the time of resection, 10 of 15 (67%) grade-discordant PanNETs had distant metastases, mostly to the liver, compared with 25 of 36 (69%) grade-concordant PanNETs (P = 1.0, Fisher exact test), and 11 of 25 (44%) had poorly differentiated NECs (P = 0.12, Fisher exact test).
Clinical Course
Follow-up information was available for all patients. At the last follow-up, 10 patients (53%) with grade-discordant PanNET had died of disease. Five patients (26%) were alive with disease, and 4 (21%) were alive with no evidence of disease. Similarly, 26 patients (49%) with grade-concordant PanNET had died of disease, and 3 (6%) died of unknown causes or other conditions. Thirteen patients (25%) with grade-concordant PanNET were alive with disease, and 11 (21%) were alive with no evidence of disease. The majority (n = 33, 80%) of the patients with poorly differentiated NEC had died of disease. Of note, 1 patient died of surgical complications, and another patient with disease died of other conditions. Only 8 (19%) were alive, and they all had disease.
Although the median survival of the patients with grade-discordant PanNETs was shorter than that of the patients with grade-concordant PanNETs (54.1 vs. 67.8 mo), the difference was not statistically significant (P = 0.2; Table 3 ). However, the median survival of the patients with grade-discordant PanNETs was significantly longer than that of poorly differentiated NECs (54.1 vs. 11 mo, P = 0.002). Similarly, 2-and 5-year disease-specific survival rates of the patients with grade-discordant PanNETs were 74.9% and 29.1%, compared with 86.7% and 62.4% for grade-concordant PanNETs, and 22.5% and 16.1% of poorly differentiated NECs, respectively (Table 3 ; Fig. 4 ). Of note, when only the patients with distant metastases were analyzed, survival did not differ between groups, but our ability to detect differences was limited by the small number of cases (P = 0.10 for gradediscordant PanNETs vs. grade-concordant PanNETs and P = 0.085 for grade-discordant PanNETs vs. poorly differentiated NECs; Fig. 5 ).
DISCUSSION
This study further supports the conclusion that the mitotic rate and Ki67 index-based grades of well differentiated PanNETs can be discordant. In our series, 19 cases that would have been G2 by mitotic rate alone were G3 by Ki67 index. It is noteworthy that none of the G2 by mitotic rate cases included in this study had a Ki67 index in the G1 range, further supporting the observation that when there is discordance in grade between the mitotic rate and the Ki67 index, it is the Ki67 index that typically points to the higher grade. 3 We also demonstrate that morphologically well differentiated PanNETs that are classified as G3 on the basis of the Ki67-labeling index alone are less aggressive than bona fide poorly differentiated (small cell or large cell type) pancreatic NECs.
Although the current European Neuroendocrine Tumor Society/WHO classification suggests that G3 NECs are part of a continuum with G1 and G2 NETs, and that grade should be based entirely on proliferation rate, evolving evidence strongly suggests that morphologic differentiation is also relevant and that poorly differentiated NECs should be regarded as a completely separate entity from well differentiated PanNETs. Supporting this concept, it has been shown recently that pancreatic small cell carcinoma and large cell NEC are genetically related entities and that the genetic changes frequently seen in these poorly differentiated carcinomas, such as inactivation of the TP53 and the Rb/p16 pathways, are rarely observed in well differentiated Pan-NETs. 8 Conversely, inactivating mutations in DAXX and ATRX and mutations in MEN1 are exclusively found in well differentiated PanNETs. 8 Thus, the molecular genetic distinction of poorly differentiated NECs from well differ-entiated NETs along with our results confirms the impression that the G3 category actually includes 2 different groups: (1) well differentiated NET with an elevated proliferative rate; and (2) poorly differentiated NEC with small cell or large cell morphology. The former is characterized by a much lower average Ki67 index (40% vs. 70%), and its outcome is not as poor as that of poorly differentiated NEC (2-and 5-y survivals of 74.9% and 29.1% vs. 22.5% and 16.1%). Furthermore, the mitotic rate of the well differentiated G3 NETs appears to be mostly in the G2 range, although the current study design (in which only discordant cases were selected) does not allow firm conclusions whether some well differentiated PanNETs with a Ki67 index in the G3 range may also have a mitotic rate >20/10 HPF.
Supporting these conclusions, the "Nordic NEC Study" found that not all patients with 2010 WHO G3 NEC benefit from platinum-based chemotherapies typically used for poorly differentiated NECs such as small cell carcinoma. G3 tumors with a Ki67 index <55% were less responsive than G3 NECs with a Ki67 index Z55%, although the latter group experienced early recurrence of shorter ultimate survival than the group with a Ki67 in the 20% to 55% range. 4 However, the pathologic features of the tumors in the "Nordic NEC Study" were not evaluated in detail, and it is unclear whether these 2 different groups strictly corresponded to well differentiated NETs and poorly differentiated NECs, respectively. Nevertheless, the current evidence suggests that if careful mitotic counting and immunolabeling for Ki67 are not performed, and if morphologic features (differentiation) are not considered, misclassification can occur, which may have important therapeutic consequences. It must also be acknowledged that neuroendocrine neoplasms exist for which the distinction of well differentiated versus poorly differentiated may be challenging, especially when the nuclear morphology is not that of small cell carcinoma. In some cases, the Ki67 index may fall in the 35% to 60% range, and the morphologic features may also be intermediate. In such cases, evaluation of molecular characteristics may prove helpful to assign the most appropriate diagnosis, but definitive data linking the mutational profile to outcome and response to therapy have yet to be generated.
Other studies have attempted to address the optimal proliferation cut-off points to stratify outcome at the lower end of the grading spectrum: 1 study of 24 patients with PanNETs found that a Ki67-labeling index >10% predicted lymph node metastases and poorer overall survival and suggests that a Ki67 index cut-off point of 10% is better than 3% as in the 2010 WHO classification. 9 Similarly, a larger study of 140 patients with PanNETs found that a Ki67 index of >9% predicted a higher likelihood of disease recurrence and poorer overall survival. 10 Currently, however, there are limited options for therapeutic stratification within the well differentiated PanNET group, on the basis of the G1 versus G2 distinction, and it is not clear whether sufficient data exist to justify a change in the proliferation cut-off points that separate G1 and G2 NETs.
Naturally, all of these findings call into question some aspects of the current grading system. Proposals for modifications to the system are currently being developed, but we believe that the current evidence suggests that mitotic G2, Ki67 G3 well differentiated PanNETs should be distinguished from true poorly differentiated NECs. One option would be to raise the Ki67 index threshold for the diagnosis of poorly differentiated NEC (eg, from 20% to 50%). However, this change would place a very broad range of proliferative rates in the G2 category, so it is important to determine whether survival differences exist between the grade-concordant (both mitotic count and Ki67 index G2) NETs and the grade-discordant (mitotic count G2/Ki67 index G3) NETs. In our study, the patients with the grade-discordant PanNETs had worse clinical outcome than did patients with grade-concordant PanNETs (median survival of 54.1 and 67.8 mo, respectively), but the difference was not statistically significant. However, the Kaplan-Meier curves show separation between the groups, and the lack of statistical significance may be due to the small number of cases and the inability to accurately correct for variations in the extent of disease, despite our attempt to stage-match the cases. Therefore, until additional data are accumulated, we advocate maintaining the separation of the pure G2 NETs from the well differentiated G3 NETs, which we now designate as well differentiated NET with an elevated proliferative rate.
It is also noteworthy that the highly aggressive nature of the true poorly differentiated NECs appears to be independent of presenting stage. This group had a worse outcome than the grade-discordant well differentiated PanNETs, despite having a smaller proportion with metastases at presentation (44% vs. 71%). However, when only the patients with distant metastasis were analyzed, survival could not be shown to differ statistically between the groups, again being limited by the small number of cases.
In summary, we report that patients with morphologically well differentiated PanNET that would be classified as grade 2 on the basis of mitotic rate and grade 3 on the basis of Ki67 index have a significantly better clinical outcome than patients with morphologically poorly differentiated NEC. The outcome for patients with PanNET classified as grade 2 by mitotic rate and grade 3 by Ki67 index also appears to be slightly worse than that of patients with PanNET concordantly classified as grade 2 by mitotic rate and Ki67 index. These findings, combined with the recent introduction of effective targeted therapies, 4 suggest that it is not correct to consider all current WHO grade 3 neuroendocrine neoplasms as a single disease entity and that a modified classification system distinguishing well differentiated neuroendocrine tumors with an elevated proliferative rate from poorly differentiated NECs is needed for more accurate treatment decisions.
